Advances in the drug management of basal cell carcinoma

References

• Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol. 2002;146(Suppl 61):1–6.
   PubMed Web of Science ®Google Scholar
• Wong CS, Strange RC, Lear JT. Basal cell carcinoma. Bmj. 2003;327(7418):794–798.
   PubMed Web of Science ®Google Scholar
• Green A. Changing patterns in incidence of non-melanoma skin cancer. Epithelial Cell Biol. 1992;1(1):47–51.
   PubMedGoogle Scholar
• Bulliard JL, Panizzon RG, Levi F. Epidemiology of epithelial skin cancers. Rev Med Suisse. 2009;5(200):882, 4–8.
   Google Scholar
• Bakshi A, Chaudhary SC, Rana M, et al. Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond. Mol Carcinog. 2017;56(12):2543–2557.
   PubMed Web of Science ®Google Scholar
• Dreier J, Cheng PF, Bogdan Alleman I, et al. Basal cell carcinomas in a tertiary referral centre: a systematic analysis. Br J Dermatol. 2014;171(5):1066–1072.
   PubMed Web of Science ®Google Scholar
• Xie P, Lefrancois P. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: a systematic review and meta-analysis. J Am Acad Dermatol. 2018;79(6):1089–100 e17.
   PubMed Web of Science ®Google Scholar
• Bonilla X, Parmentier L, King B, et al. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet. 2016;48(4):398–406.
   PubMed Web of Science ®Google Scholar
• Otsuka A, Dreier J, Cheng PF, et al. Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma. Clin Cancer Res. 2015;21(6):1289–1297.
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Lilo MT, Ogurtsova A, et al. Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. J Immunother Cancer. 2017;5(1):23.
   PubMedGoogle Scholar
• Mohan SV, Kuo KY, Chang AL. Incidental regression of an advanced basal cell carcinoma after ipilimumab exposure for metastatic melanoma. JAAD Case Rep. 2016;2(1):13–15.
   PubMedGoogle Scholar
• Winkler JK, Schneiderbauer R, Bender C, et al. Anti-programmed cell death-1 therapy in nonmelanoma skin cancer. Br J Dermatol. 2017;176(2):498–502.
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Kim HJ, Villasboas JC, et al. Expression of LAG-3 defines exhaustion of intratumoral PD-1(+) T cells and correlates with poor outcome in follicular lymphoma. Oncotarget. 2017;8(37):61425–61439.
   PubMedGoogle Scholar
• Peris K, Fargnoli MC, Garbe C, et al. Diagnosis and treatment of basal cell carcinoma: european consensus-based interdisciplinary guidelines. Eur J Cancer. 2019;118:10–34.
   PubMed Web of Science ®Google Scholar
• Grob JJ, Guminski A, Malvehy J, et al., Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition. J Eur Acad Dermatol Venereol. 35(10): 1949–1956. 2021.
   PubMed Web of Science ®Google Scholar
• Grob JJ, Gaudy-Marqueste C, Guminski A, et al. Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas. J Eur Acad Dermatol Venereol. 2021;35(11):2149–2153.
   PubMed Web of Science ®Google Scholar
• Kim DJ, Kim J, Spaunhurst K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol. 2014;32(8):745–751.
   PubMed Web of Science ®Google Scholar
• Hanna E, Abadi R, Abbas O. Imiquimod in dermatology: an overview. Int J Dermatol. 2016;55(8):831–844.
   PubMed Web of Science ®Google Scholar
• Arits AH, Mosterd K, Essers BA, et al., Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 14(7): 647–654. 2013.
   PubMed Web of Science ®Google Scholar
• Jansen MHE, Mosterd K, Arits A, et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. J Invest Dermatol. 2018;138(3):527–533.
   PubMed Web of Science ®Google Scholar
• Williams HC, Bath-Hextall F, Ozolins M, et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. J Invest Dermatol. 2017;137(3):614–619.
   PubMed Web of Science ®Google Scholar
• Roozeboom MH, Arits A, Mosterd K, et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. J Invest Dermatol. 2016;136(8):1568–1574.
   PubMed Web of Science ®Google Scholar
• Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007;26(37):5420–5432.
   PubMed Web of Science ®Google Scholar
• Mirza AN, McKellar SA, Urman NM, et al. LAP2 proteins chaperone GLI1 movement between the lamina and chromatin to regulate transcription. Cell. 2019;176(1–2):198–212 e15.
   PubMed Web of Science ®Google Scholar
• Peer E, Tesanovic S, Aberger F. Next-generation Hedgehog/GLI pathway inhibitors for cancer therapy. Cancers (Basel). 2019;11(4):538.
   Web of Science ®Google Scholar
• Coni S, Mancuso AB, Di Magno L, et al. Corrigendum: selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma. Sci Rep. 2017;7(1):46645.
   PubMedGoogle Scholar
• Mirza AN, Fry MA, Urman NM, et al. Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment. JCI Insight. 2017;2(21). DOI:https://doi.org/10.1172/jci.insight.97071.
   Google Scholar
• Kilgour JM, Shah A, Urman NM, et al. Phase II open-label, single-arm trial to investigate the efficacy and safety of topical remetinostat gel in patients with basal cell carcinoma. Clin Cancer Res. 2021;27(17):4717–4725.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Nishida N, Yano H, Nishida T, et al. Angiogenesis in cancer. Vasc Health Risk Manag. 2006;2(3):213–219.
   PubMedGoogle Scholar
• Carbone A, Viola P, Varrati S, et al. Microvessel density and VEGF expression seems to correlate with invasiveness of basal cell carcinoma. Eur J Dermatol. 2011;21(4):608–609.
   PubMed Web of Science ®Google Scholar
• Oh CK, Kwon YW, Kim YS, et al. Expression of basic fibroblast growth factor, vascular endothelial growth factor, and thrombospondin-1 related to microvessel density in nonaggressive and aggressive basal cell carcinomas. J Dermatol. 2003;30(4):306–313.
   PubMed Web of Science ®Google Scholar
• Johnson KE, Wilgus TA. Multiple roles for VEGF in non-melanoma skin cancer: angiogenesis and beyond. J Skin Cancer. 2012;2012:483439.
   PubMedGoogle Scholar
• Hanna A, Shevde LA. Hedgehog signaling: modulation of cancer properties and tumor mircroenvironment. Mol Cancer. 2016;15(1):24.
   PubMedGoogle Scholar
• Syed V. TGF-beta signaling in cancer. J Cell Biochem. 2016;117(6):1279–1287.
   PubMed Web of Science ®Google Scholar
• Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol. 2012;13(10):616–630.
   PubMed Web of Science ®Google Scholar
• Kuonen F, Surbeck I, Sarin KY, et al. TGFbeta, fibronectin and integrin alpha5beta1 promote invasion in basal cell carcinoma. J Invest Dermatol. 2018;138(11):2432–2442.
   PubMed Web of Science ®Google Scholar
• Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999;18(55):7908–7916.
   PubMed Web of Science ®Google Scholar
• El-Khalawany MA, Abou-Bakr AA. Role of cyclooxygenase-2, ezrin and matrix metalloproteinase-9 as predictive markers for recurrence of basal cell carcinoma. J Cancer Res Ther. 2013;9(4):613–617.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu J. The prognostic roles of cyclooxygenase-2 for patients with basal cell carcinoma. Artif Cells Nanomed Biotechnol. 2019;47(1):3053–3057.
   PubMed Web of Science ®Google Scholar
• Armas-Lopez L, Zuniga J, Arrieta O, et al. The Hedgehog-GLI pathway in embryonic development and cancer: implications for pulmonary oncology therapy. Oncotarget. 2017;8(36):60684–60703.
   PubMedGoogle Scholar
• Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85(6):841–851.
   PubMed Web of Science ®Google Scholar
• Silapunt S, Chen L, Migden MR. Hedgehog pathway inhibition in advanced basal cell carcinoma: latest evidence and clinical usefulness. Ther Adv Med Oncol. 2016;8(5):375–382.
   PubMed Web of Science ®Google Scholar
• Villani A, Cinelli E, Fabbrocini G, et al. Hedgehog inhibitors in the treatment of advanced basal cell carcinoma: risks and benefits. Expert Opin Drug Saf. 2020;19(12):1585–1594.
   PubMed Web of Science ®Google Scholar
• Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–2179.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Gutzmer R, Kieran MW, et al. Hedgehog signaling inhibitors in solid and hematological cancers. Cancer Treat Rev. 2019;76:41–50.
   PubMed Web of Science ®Google Scholar
• Dummer R, Ascierto PA, Basset-Seguin N, et al., Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. J Eur Acad Dermatol Venereol. 34(9): 1944–1956. 2020.
   PubMed Web of Science ®Google Scholar
• Whitson RJ, Lee A, Urman NM, et al. Noncanonical hedgehog pathway activation through SRF-MKL1 promotes drug resistance in basal cell carcinomas. Nat Med. 2018;24(3):271–281.
   PubMed Web of Science ®Google Scholar
• Yauch RL, Dijkgraaf GJ, Alicke B, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science. 2009;326(5952):572–574.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–2501.
   PubMed Web of Science ®Google Scholar
• Chang J, Zhu GA, Cheung C, et al. Association between programmed death ligand 1 expression in patients with basal cell carcinomas and the number of treatment modalities. JAMA Dermatol. 2017;153(4):285–290.
   PubMed Web of Science ®Google Scholar
• Sabbatino F, Marra A, Liguori L, et al. Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature. J Immunother Cancer. 2018;6(1):126.
   PubMedGoogle Scholar
• Stratigos AJ, Sekulic A, Peris K, et al., Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 22(6): 848–857. 2021.
   PubMed Web of Science ®Google Scholar
• Migden MR, Khushalani NI, Chang ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020;21(2):294–305.
   PubMed Web of Science ®Google Scholar
• Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847–856.
   PubMed Web of Science ®Google Scholar
• Sharpe HJ, Pau G, Dijkgraaf GJ, et al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell. 2015;27(3):327–341.
   PubMed Web of Science ®Google Scholar
• Peukert S, He F, Dai M, et al. Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened. ChemMedChem. 2013;8(8):1261–1265.
   PubMed Web of Science ®Google Scholar
• Gendreau SB, Hawkins D, Ho CP, et al. Abstract B192: preclinical characterization of BMS‐833923 (XL139), a hedgehog (HH) pathway inhibitor in early clinical development. Mol Cancer Ther. 2009;8(12 Supplement):B192–B.
   Web of Science ®Google Scholar
• Siu LL, Papadopoulos K, Alberts SR, et al. A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. J Clin Oncol. 2010;28(15_suppl):2501.
   Web of Science ®Google Scholar
• Bender MH, Hipskind PA, Capen AR, et al. Abstract 2819: identification and characterization of a novel smoothened antagonist for the treatment of cancer with deregulated hedgehog signaling. Cancer Res. 2011;71(8 Supplement):2819.
   Google Scholar
• Bendell J, Andre V, Ho A, et al. Abstract B32: LY2940680, a hedgehog (Hh) pathway inhibitor, demonstrates anti-tumor activity in patients with advanced basal cell carcinoma (BCC). Mol Cancer Ther. 2015;14(12 Supplement 2):B32–B.
   Google Scholar
• Pricl S, Cortelazzi B, Dal Col V, et al. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Mol Oncol. 2015;9(2):389–397.
   PubMed Web of Science ®Google Scholar
• Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17(4):388–399.
   PubMed Web of Science ®Google Scholar
• Myers BR, Neahring L, Zhang Y, et al. Rapid, direct activity assays for Smoothened reveal Hedgehog pathway regulation by membrane cholesterol and extracellular sodium. Proc Natl Acad Sci U S A. 2017;114(52):E11141–E50.
   PubMed Web of Science ®Google Scholar
• Ramelyte E, Restivo G, Imhof L, et al. How to break resistance to hedgehog inhibitors in advanced basal cell carcinoma? Br J Dermatol. 2021;184(2):359–361.
   PubMed Web of Science ®Google Scholar
• Kasper M, Regl G, Frischauf A-M, et al. GLI transcription factors: mediators of oncogenic Hedgehog signalling. Eur J Cancer. 2006;42(4):437–445.
   PubMed Web of Science ®Google Scholar
• Ingham PW, Nakano Y, Seger C. Mechanisms and functions of Hedgehog signalling across the metazoa. Nat Rev Genet. 2011;12(6):393–406.
   PubMed Web of Science ®Google Scholar
• Hui CC, Angers S. Gli proteins in development and disease. Annu Rev Cell Dev Biol. 2011;27(1):513–537.
   PubMedGoogle Scholar
• Lauth M, Bergstrom A, Shimokawa T, et al. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A. 2007;104(20):8455–8460.
   PubMed Web of Science ®Google Scholar
• Wickstrom M, Dyberg C, Shimokawa T, et al. Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo. Int J Cancer. 2013;132(7):1516–1524.
   PubMed Web of Science ®Google Scholar
• Chen Q, Xu R, Zeng C, et al. Down-regulation of Gli transcription factor leads to the inhibition of migration and invasion of ovarian cancer cells via integrin beta4-mediated FAK signaling. PLoS One. 2014;9(2):e88386.
   PubMed Web of Science ®Google Scholar
• Jia H, Liu Y, Xia R, et al. Casein kinase 2 promotes Hedgehog signaling by regulating both smoothened and Cubitus interruptus. J Biol Chem. 2010;285(48):37218–37226.
   PubMed Web of Science ®Google Scholar
• Jia J, Jiang J. Decoding the Hedgehog signal in animal development. Cell Mol Life Sci. 2006;63(11):1249–1265.
   PubMed Web of Science ®Google Scholar
• Trembley JH, Wang G, Unger G, et al. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci. 2009;66(11–12):1858–1867.
   PubMedGoogle Scholar
• Zhang S, Wang Y, Mao JH, et al. Inhibition of CK2alpha down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells. PLoS One. 2012;7(6):e38996.
   PubMed Web of Science ®Google Scholar
• Giroux-Leprieur E, Costantini A, Ding VW, et al. Hedgehog signaling in lung cancer: from oncogenesis to cancer treatment resistance. Int J Mol Sci. 2018;19(9):2835.
   Web of Science ®Google Scholar
• Purzner T, Purzner J, Buckstaff T, et al. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma. Sci Signal. 2018;11(547). DOI:https://doi.org/10.1126/scisignal.aau5147.
   Google Scholar
• Chang ALS, Tran DC, Cannon JGD, et al. Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study. J Am Acad Dermatol. 2019;80(2):564–566.
   PubMed Web of Science ®Google Scholar
• Ma J, Mo Y, Tang M, et al. Bispecific antibodies: from research to clinical application. Front Immunol. 2021;12:626616.
   PubMed Web of Science ®Google Scholar
• Schmid AS, Neri D. Advances in antibody engineering for rheumatic diseases. Nat Rev Rheumatol. 2019;15(4):197–207.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Demeure CE, Wolfers J, Martin-Garcia N, et al. T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts. Eur J Cancer. 2001;37(13):1709–1718.
   PubMed Web of Science ®Google Scholar
• Durham NM, Nirschl CJ, Jackson CM, et al. Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo. PLoS One. 2014;9(11):e109080.
   PubMed Web of Science ®Google Scholar
• Pena J, Jones NG, Bousheri S, et al. Lymphocyte activation gene-3 expression defines a discrete subset of HIV-specific CD8+ T cells that is associated with lower viral load. AIDS Res Hum Retroviruses. 2014;30(6):535–541.
   PubMed Web of Science ®Google Scholar
• Huang CT, Workman CJ, Flies D, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21(4):503–513.
   PubMed Web of Science ®Google Scholar
• Grosso JF, Goldberg MV, Getnet D, et al. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol. 2009;182(11):6659–6669.
   PubMed Web of Science ®Google Scholar
• Solinas C, Migliori E, De Silva P, et al. LAG3: the biological processes that motivate targeting this immune checkpoint molecule in human cancer. Cancers (Basel). 2019;11(8):1213.
   Web of Science ®Google Scholar
• Lipson EJ, Tawbi -HA-H, Schadendorf D, et al. Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: primary phase III results from RELATIVITY-047 (CA224-047). J Clin Oncol. 2021;39(15_suppl):9503.
   Google Scholar
• Khagi Y, Kurzrock R, Patel SP. Next generation predictive biomarkers for immune checkpoint inhibition. Cancer Metastasis Rev. 2017;36(1):179–190.
   PubMed Web of Science ®Google Scholar
• Miura JT, Zager JS. Intralesional therapy as a treatment for locoregionally metastatic melanoma. Expert Rev Anticancer Ther. 2018;18(4):399–408.
   PubMed Web of Science ®Google Scholar
• Malek TR. The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol. 2003;74(6):961–965.
   PubMed Web of Science ®Google Scholar
• van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist. 2006;11(4):397–408.
   PubMed Web of Science ®Google Scholar
• Bartsch HH, Pfizenmaier K, Schroeder M, et al. Intralesional application of recombinant human tumor necrosis factor alpha induces local tumor regression in patients with advanced malignancies. Eur J Cancer Clin Oncol. 1989;25(2):287–291.
   PubMedGoogle Scholar
• Lieverse RIY, Marcus D, van der Wiel AMA, et al. Human fibronectin extra domain B as a biomarker for targeted therapy in cancer. Mol Oncol. 2020;14(7):1555–1568.
   PubMed Web of Science ®Google Scholar
• Danielli R, Patuzzo R, Di Giacomo AM, et al. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. Cancer Immunol Immunother. 2015;64(8):999–1009.
   PubMed Web of Science ®Google Scholar
• Blackmon JT, Dhawan R, Viator TM, et al. Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: a report of 2 cases. JAAD Case Rep. 2017;3(3):185–189.
   PubMedGoogle Scholar
• Ramelyte E, Tastanova A, Balazs Z, et al. Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective. Cancer Cell. 2021;39(3):394–406 e4.
   PubMed Web of Science ®Google Scholar
• Ni L, Lu J. Interferon gamma in cancer immunotherapy. Cancer Med. 2018;7(9):4509–4516.
   PubMed Web of Science ®Google Scholar
• Kochupurakkal BS, Wang ZC, Hua T, et al. RelA-induced interferon response negatively regulates proliferation. PLoS One. 2015;10(10):e0140243.
   PubMed Web of Science ®Google Scholar
• Wang QS, Shen SQ, Sun HW, et al. Interferon-gamma induces autophagy-associated apoptosis through induction of cPLA2-dependent mitochondrial ROS generation in colorectal cancer cells. Biochem Biophys Res Commun. 2018;498(4):1058–1065.
   PubMed Web of Science ®Google Scholar
• Kammertoens T, Friese C, Arina A, et al. Tumour ischaemia by interferon-gamma resembles physiological blood vessel regression. Nature. 2017;545(7652):98–102.
   PubMed Web of Science ®Google Scholar
• Aqbi HF, Wallace M, Sappal S, et al. IFN-gamma orchestrates tumor elimination, tumor dormancy, tumor escape, and progression. J Leukoc Biol. 2018;103(6):1219–1223.
   Web of Science ®Google Scholar
• Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002;13(2):95–109.
   PubMed Web of Science ®Google Scholar
• Dey A, Varelas X, Guan KL. Targeting the hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov. 2020;19(7):480–494.
   PubMed Web of Science ®Google Scholar
• Biehs B, Dijkgraaf GJP, Piskol R, et al. A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition. Nature. 2018;562(7727):429–433.
   PubMed Web of Science ®Google Scholar
• Jung YS, Park JI. Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond beta-catenin and the destruction complex. Exp Mol Med. 2020;52(2):183–191.
   PubMed Web of Science ®Google Scholar
• Sahai E, Astsaturov I, Cukierman E, et al., A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 20(3): 174–186. 2020.
   PubMed Web of Science ®Google Scholar